Prof. Dr. med. Thomas Pabst
https://pubmed.ncbi.nlm.nih.gov/?term=Pabst+Thomas%5BAuthor%5D&sort=
PD Dr. Katja Seipel
2022
Seipel K, Bruegger Y, Mandhair H, Bacher U, Pabst T. Rationale for combining the BCL2 inhibitor venetoclax with the PI3K inhibitor bimiralisib in the treatment of IDH2 and FLT3 mutated acute myeloid leukemia. Int. J. Mol. Sci. 2022, 23, 12587. https://doi.org/10.3390/ijms232012587. PMID: 36293442
Heini A, Bacher U, Porret N, Wiedemann G, Seipel K, Novak U, Daskalakis M, Pabst T. Enhanced expansion of CD19 CAR T cells after administration of CD20/CD3 bispecific antibodies in patients with relapsed mantle cell lymphoma. cells. mdpi. Communication. Cells 2022 Sep 2;11(17):2747. doi: 10.3390/ cells 1117274. PMID: 36078155
Rentsch V, Seipel K, Banz Y, Wiedemann G, Porret N, Bacher U, Pabst T. Glofitamab treatment in relapsed or refractory DLBCL after CAR T-cell therapy. Cancers (Basel). 2022 May 20;14(10):2516. doi: 10.3390/cancers 14102516. PMID: 35626120
Seipel K, Porret N, Wiedemann G, Jeker B, Bacher U, Pabst T. sBCMA plasma level dynamics and anti-BCMA treatment in relapsed Multiple Myeloma. Curr. Issues Mol. Biol. 2022, 44, 1463–1471. Curr Issues Mol Biol. 2022 Mar 24;44(4):1463-1471. doi: 10.3390/cimb44040098. PMID: 35723356
2021
Seipel K, Graber C, Flückiger L, Bacher U, Pabst T. Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia. Int J Mol Sci. 2021 Jul 28;22(15):8092. doi: 10.3390/ijms22158092. PMID: 34360855; PMCID: PMC8347059.
Seipel K, Kopp B, Bacher U, Pabst T. BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia. Cancers (Basel). 2021 Feb 2;13(3):581. doi: 10.3390/cancers13030581. PMID: 33540760; PMCID: PMC7867282.
Messikommer A, Seipel K, Byrne S, Valk P, Pabst T, Luedtke NW. RNA Targeting in Acute Myeloid Leukemia. ACS Pharmacol Transl Sci. 2020 Oct 12;3(6):1225-1232. doi: 10.1021/acsptsci. 0c00120. eCollection 2020 Dec 11. PMID: 33344899.
2020
Idle JR, Seipel K, Bacher U, Pabst T, Beyoğlu D. (2R,3S)-Dihydroxybutanoic Acid Synthesis as a Novel Metabolic Function of Mutant Isocitrate Dehydrogenase 1 and 2 in Acute Myeloid Leukemia. Cancers (Basel). 2020 Oct 1;12(10):2842. doi: 10.3390/cancers12102842. PMID: 33019704; PMCID: PMC7600928.
Pabst T, Joncourt R, Shumilov E, Heini A, Wiedemann G, Legros M, Seipel K, Schild C, Jalowiec K, Mansouri Taleghani B, Fux M, Novak U, Porret N, Zeerleder S, Bacher U. Analysis of IL-6 serum levels and CAR T cell-specific digital PCR in the context of cytokine release syndrome. Exp Hematol. 2020 Aug;88:7-14.e3. doi: 10.1016/j.exphem.2020.07.003. Epub 2020 Jul 13. PMID: 32673688.
Seipel K, Messerli C, Wiedemann G, Bacher U, Pabst T. MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation. Leuk Res. 2020 Feb;89:106296. doi: 10.1016/j.leukres.2020.106296. Epub 2020 Jan 3. PMID: 31927137.
2019
Seipel K, Schmitter K, Bacher U, Pabst T. Rationale for a Combination Therapy Consisting of MCL1- and MEK-Inhibitors in Acute Myeloid Leukemia. Cancers (Basel). 2019 Nov 12;11(11):1779. doi: 10.3390/cancers11111779. PMID: 31718075; PMCID: PMC6896073.
Hitz F, Kraus M, Pabst T, Hess D, Besse L, Silzle T, Novak U, Seipel K, Rondeau S, Stüdeli S, Vilei SB, Samaras P, Mey U, Driessen C; Swiss Group for Clinical Cancer Research SAKK. Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10). Blood Cancer J. 2019 Aug 27;9(9):70. doi: 10.1038/s41408-019-0228-2. PMID: 31455773; PMCID: PMC6711992.
Schnell BR, Seipel K, Bacher U, Jeker B, Mueller BU, Banz Y, Novak U, Pabst T. Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML Patients. Hemasphere. 2019 Mar 20;3(2):e180. doi: 10.1097/HS9.0000000000000180. PMID: 31723819; PMCID: PMC6746035.
